创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

ZHANG Jingxue, ZHANG Yibin, YU Ziheng, FENG Jie, LU Tao. Research Progress of DNA Polymerase θ Inhibitors[J]. Progress in Pharmaceutical Sciences, 2025, 49(5): 360-372. DOI: 10.20053/j.issn1001-5094.20250057
Citation: ZHANG Jingxue, ZHANG Yibin, YU Ziheng, FENG Jie, LU Tao. Research Progress of DNA Polymerase θ Inhibitors[J]. Progress in Pharmaceutical Sciences, 2025, 49(5): 360-372. DOI: 10.20053/j.issn1001-5094.20250057

Research Progress of DNA Polymerase θ Inhibitors

  • DNA polymerase θ (Pol θ), the only eukaryotic DNA polymerase currently known to possess both helicase and polymerase activities, plays a crucial role in DNA double-strand break (DSB) repair pathway-microhomology-mediated end joining (MMEJ). The synthetic lethality of Pol θ in homologous recombination deficiency (HRD) tumors has garnered significant attention in recent years. And Pol θ has become one of the pivotal anticancer targets in the research and development of numerous domestic and foreign pharmaceutical companies. This paper systematically reviews the structure and function of Pol θ protein and the latest research progress of small-molecule inhibitors, which is beneficial for further development of more efficient and specific Pol θ-targeted inhibitors for precision treatment of HRD tumors.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return